How to Cite
Abstract
Results of numerous retrospective studies have confirmed that the degree of cytoreduction and the size of the residual tumor after the primary surgery are the most important factors affecting overall life expectancy as well as the time to progression in patients with ovarian cancer (OC). The article presents the immediate results of the first 16 extensive cytoreductive surgeries in advanced OC performed at the Oncogynecology Department of the N.N. Petrov National Medical Research Center of Oncology.References
Chi D., Franklin C.C., Levine D.A. et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach//Gynecol. Oncol. -2004. -Vol. 94. -P. 650-654.
Gerestein C., Nieuwenhuyzende Boer G.M, Eijkemans M.J. et al. Prediction of 30-day morbidity after primary cytoreductive surgery for advanced stage ovarian cancer//Eur. J. Cancer. -2010. -Vol. 46(1). -P. 102-129.
Guidozzi F., Ball J.H.s. Extensive primary cytoreductive surgery for advanced epithelial ovarian cancer//Gynecol. Oncol. -1994. -Vol. 53. -P. 326-330.
Hofstetter G., Concin N, Braicu I. et al. The time interval from surgery to start of chemotherapy significantly im pacts prognosis in patients with advanced serous ovarian carcinoma -Analysis of patient data in the prospective OVCAD study//Gynecol. Oncol. -2013. -Vol. 131(1). -P. 15-20.
Hoskins W., Bundy B.N., Thigpen J.T et al. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study//Gynecol. Oncol. -1992. -Vol. 47. -P. 159-166.
Karlsen M., Fagö-Olsen C., H0gdall E. et al. A novel index for preoperative, non-invasive prediction of macroradical primary surgery in patients with stage IIIC-IV ovarian cancer-a part of the Danish prospective pelvic mass study//Tumour Biol. -2016. -Vol. 37(9). -P. 12619-12626.
Mahner s., Eulenburg C., staehle A. et al. Prognostic impact of the time interval between primary surgery and chemotherapy in patients with advanced ovarian cancer: analysis of prospective randomized phase III trials//Eur. J. Cancer. -2013. -Vol. 49. -P 142-149.
Martin R., Brennan M.F., Jaques D.P Quality of complication reporting in the surgical literature//Ann. surg. -2002. -Vol. 235. -P. 803-813.
Piver M., Lele S.B., Marchetti D.L. et al. The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma//J. Clin. Oncol. -1988. -Vol. 6. -P. 983-989.
Salani R., Axtell A., Gerardi M. et al. Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer//Gynecol. Oncol. -2008. -Vol. 108(2). -P. 271-275.
Sugarbaker P. A perspective on clinical research strategies in carcinoma of the large bowel//World J. surg. -1991. -Vol. 15. -P. 609-616.
Sugarbaker P., Jablonski K.A. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy//Ann. Surg. -1995. -Vol. 221. -P. 124-132.
Sugarbaker P. Pseudomyxoma peritonei. A cancer whose biology is characterized by a redistribution phenomenon//Ann. Surg. -1994. -Vol. 219. -P. 109-111.
Wright J., Doan T., McBride R. et al. Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival//Br. J. Cancer. -2008. -Vol. 98. -P. 1197-1203.
Wright J., Herzog T.J., Neugut A.I. et al. Effect of radical cytoreductive surgery on omission and delay of chemotherapy for advance-stage ovarian cancer//Obstet. Gynecol. -2012. -Vol. 120. -P. 871-881.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2018